A Covid-19 vaccine study funded by the French government and conducted by university researchers have confirmed the elevated risk of heart inflammation with Covid ‘boosters,’ particularly with the Moderna series.
“In the study, French researchers analyzed 4,890 myocarditis cases admitted to hospitals in the country between Dec. 27, 2020, and Jan. 31, 2022,” the Epoch Times reported. The researchers used 48,900 controls from the general population.
The COVID-19 vaccine booster was associated with an elevated risk of myocarditis, a form of heart inflammation, particularly after the Moderna booster. The adjusted heart inflammation risk was three times higher for those who took a Pfizer booster and four times higher after a Moderna booster.
The risk was 4.9 times higher for Pfizer booster recipients aged 12 to 29. The Moderna series has been suspended for patients under 30 years old in France, thus data for that age group was not available.
“We found that the risk of myocarditis remained elevated after the booster dose and that longer intervals between each consecutive dose (including booster doses) may decrease the occurrence of vaccine-associated myocarditis,” the researchers found.
For those over 30 years old, a Pfizer booster was associated with a 2.4 times higher risk of heart inflammation and Moderna’s booster carried a 4.1 times higher risk.
"*" indicates required fields
The Journal of Clinical Medicine in March found in a new large population study that the recent surge in myocarditis and pericarditis cases, both indicative of heart inflammation, are not associated with natural Covid-19 infection.
“We did not observe an increased incidence of neither pericarditis nor myocarditis in adult patients recovering from COVID-19 infection,” the authors concluded.
An Oxford University study earlier showed that the risk of myocarditis, a form of heart inflammation, is greater from getting ‘vaccinated’ with the mRNA shots than from contracting the virus itself. The study was originally published in Nature in December.
“This is the largest study to date of acute cardiac outcomes after SARS-CoV-2 vaccination or infection, the first to compare the risk of cardiac events between different vaccine products and SARS-CoV2 infection and the first to investigate the association between cardiac events and the ChAdOx1 vaccine,” the study stated.
The French study thus adds to a growing body of research that suggests that the risks of taking the Covid vaccines outweighs the benefits, especially given the near-complete Covid antibody seroprevalence in the U.S. population, the reduced deadliness of current Covid variants, and the lower risk for those who do not have multiple comorbidities.
In 2021, insurance companies reported there was a 40% increase in all-cause deaths, despite the Covid vaccines.
The insurance companies reported an “overwhelming” and “unexplained” increase among 18-49 year-olds, according to a KUSI report.